Effect of amiodarone and sotalol on ventricular defibrillation threshold: The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial

Circulation

Volumn 114, Issue 2, 2006, Pages 104-109

  Hohnloser, Stefan H ^a   Dorian, Paul ^b   Roberts, Robin ^c   Gent, Michael ^c   Israel, Carsten W ^a   Fain, Eric ^d   Champagne, Jean ^e   Connolly, Stuart J ^c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST JUDE MEDICAL   (United States)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antiarrhythmia agents; Defibrillation; Tachyarrhythmias

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; SOTALOL; ANTIARRHYTHMIC AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; DEFIBRILLATOR; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BISOPROLOL; CARBAZOLES; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART ARREST; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; SOTALOL; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 33747070573     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.618421     Document Type: Article

References (32)

1. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Overview of the implantable cardioverter secondary prevention trials. Eur Heart J. 2000;21:2071-2078.
2. Moss AJ, Zarebra W, Hall WJ, Klein H, Wilber DJ, Cannom DS; Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
3. Bardy GH, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
4. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2152-2158.
5. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-2879.
6. Page RL. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Am J Cardiol. 2000;85:1481-1485.
7. Steinberg JS, Martins J, Sadanandan S, Goldner B, Menchavez E, Domanski M, Russo A, Tullo A. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmic Versus Implantable Defibrillators (AVID) study. Am Heart J. 2001;142:520-529.
8. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol. 1993;72:72A-79A.
9. Fain ES, Lee JH, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Hear J. 1987;114:8-17.
10. Frame LH. The effect of oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. Pacing Clin Electrophysiol. 1989;12:339-346.
11. Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992;70:1023-1027.
12. Pelosi F Jr, Oral H, Kim MH, Sticherling C, Horwood I, Knight BP, Michaud GF, Morady F, Strickberger SA. Effects of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol. 2000;11:736-740.
13. Heart Rhythm Society. Washington advocacy. Available at: http://www.HRSonline.org/swAdvocacyFiles/advocacy103475363.asp. Accessed October, 2005.
14. Connolly JS, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld G, Hohnloser SH. Comparison of beta blockers, amiodarone plus beta blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. JAMA. 2006;295:165-171.
15. Malkin RA, Herre JM, McGowen L, Tenzer MM, Onufer JR, Stamato NJ, Wood M, Bernstein RC. A four-shock Bayesian up-down estimator of the 80% effective defibrillation dose. J Cardiovasc Electrophysiol. 1999;10:973-980.
16. Strickberger SA, Daoud EG, Davidson T, Weiss R, Bogun F, Knight BP, Bahi M, Goyal R, Man KC, Morady F. Probability of successful defibrillation at multiples of the defibrillation energy requirement in patients with an implantable defibrillator. Circulation. 1997;96:1217-1223.
17. Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk MM, Peters RW, Gold MR. Temporal decline in defibrillation thresholds with an active pectoral lead system. J Am Coll Cardiol. 2001;38:1150-1155.
18. Gold MR, Higgins S, Klein R Gilliam FR, Kopelman H, Hessen S, Payne J, Strickberger SA, Breiter D, Hahn S. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation. Circulation. 2002;105:2043-2048.
19. Venditti F, Martin D, Vassolas G, Bowen S. Rise in chronic defibrillation threshold in nonthoracotomy implantable defibrillator. Circulation. 1994;89:216-223.
20. Poole J, Bardy G, Dolack G, Kudenchuk PJ, Anderson J, Johnson G. Serial defibrillation threshold in man: a prospective controlled study. J Cardiovasc Electrophysiol. 1995;6:19-25.
21. Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997;30:233-236.
22. Tokano T, Pelosi F, Flemming M, Horwood L, Souza JJ, Zivin A, Knight BP, Goyal R, Man KC, Morady F, Strickberger SA. Long-term evaluation of the ventricular defibrillation energy requirement. J Cardiovasc Electrophysiol. 1998;9:916-920.
23. Arredono MT, Guillen SG, Quinteiro RA. Ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. Eur J Pharmacol. 1986;125:23-28.
24. Zhiou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998;31:1672-1678.
25. Dorian P. Amiodarone and defibrillation threshold: a clinical conundrum. J Cardiovasc Electrophysiol. 2000;11:741-743.
26. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ. Clinical characteristics and outcome of patients with high defibrillation thresholds: a multicenter study. Circulation. 1992;86:1206-1216.
27. Khalighi K, Daly B, Leino EV, Shorofsky SR, Kavesh NG, Peters RW, Gold MR. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997;79:150-153.
28. Shukla HH, Flaker GC, Jayam V, Roberts D. High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. Pacing Clin Electrophysiol. 2003;26:44-48.
29. Kühlkamp V, Mewis C, Suchalla R, Mermi J, Dörnberger V, Seipel L. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol. 1999;69:271-279.
30. Hodgson DFM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002;25:408-413.
31. Wang M, Dorian P. DL and D sotalol decrease defibrillation energy requirements. Pacing Clin Electrophysiol. 1989;12:1522-1529.
32. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, Verdino RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm. 2005;2:456-461.